University of South Florida

Edward Turos

Praveen Ramaraju

Kevin D Revell

Faeez Mahzamani

Rajesh Kumar Mishra

Ryan Scott Cormier

Q Ping Dou

David M Smith

Kerriann Greenhalgh

Renaud Sicard

Michelle Leslie

Biplob Bhattacharya

Raphael Labruere

Thomas J Koob

Burt E Anderson

Daniel Van Lim

Julio Garay

Ashleigh Brooke Bachman

Cristina M Coates

Kristy Lineth Flores

John C Thomas

Rebecca J Kapolka

Glenn Roma

Edward T Carpenter

Sonja S Dickey

Timothy Long

Jeung-Yeop Shim

The subject invention pertains to polyacrylate homopolymers produced from acrylolated drug monomers. The homopolymers can be produced in the form of nanoparticles. The nanoparticles comprising the homopolymers can be produced via a free radical-induced emulsion polymerization of the acrylolated drug monomers to produce an aqueous emulsion of uniformly sized nanoparticles. The homopolymers of the invention containing acrylolated antibiotic monomers can be active against Gram-positive and Gram-negative bacteria, such asand. Accordingly, methods are provided of treating a disease, for example, an infection, by administering to a subject the homopolymers, homopolymeric nanoparticles, or emulsions containing homopolymeric nanoparticles of the invention.

Nanoparticles carrying antibiotics

The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using Pluronic F68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases. Kinetics experiments in phosphate buffer indicate that 78% of the coumarin-6 was encapsulated within the polymer matrix of the nanoparticle, and the residual 22% of coumarin-6 was surface-bound and quickly released. The nanoparticles are non-toxic in vitro towards human epithelial cells (IC&#x3e;1000 &#x3bc;g/mL) and primary bovine primary aortic endothelial cells (IC&#x3e;500 &#x3bc;g/mL), and exert non-observable bactericidal activity against a selection of representative test microbes (MIC&#x3e;250 &#x3bc;g/mL). Poly(vinyl benzoate) nanoparticles are suitable carriers for molecular delivery of lipophilic small molecules such as drugs pharmaceutical and imaging agents.

Poly(vinyl benzoate) nanoparticles for molecular delivery

Synthetically-derived S,S-heterodisubstituted disulfides that exhibit potent in vitro antibacterial activity against a variety of bacteria, including, methicillin-resistantand. The present invention provides compounds, methods and compositions effective to treat microbial/bacterial infections, and, especially, infections arising from bacteria which have developed resistance to conventional antibiotics.

Antibacterial S-heterosubstituted disulfides

Embodiments of the present disclosure provide for compositions including an antibiotic containing a N-thiolated beta-lactam moiety, pharmaceutical compositions including the antibiotic, methods of treatment of a condition (e.g., bacterial infection), methods of treatment using compositions or pharmaceutical compositions, and the like.

Antibiotic compositions and methods of use

The present invention provides N-alkylthio &#x3b2;-lactams and disulfide compounds (e.g., alkyl-coenzyme A asymmetric disulfides or aryl-alkyl disulfides), compositions containing such compounds, and methods of their use as anti-bacterial agents.

N-alkylthio beta-lactams, alkyl-coenzyme A asymmetric disulfides, and aryl-alkyl disulfides as anti-bacterial agents

The subject invention pertains to formulations comprising poly(menthyl acrylate) nanoparticles comprising at least one active ingredient contained in a plurality of hydrophobic carriers and dispersed in an aqueous medium. The subject invention further pertains to methods of polymerization of drug loaded nanoparticles made up of methyl acrylate monomers in an aqueous emulsion.

Menthol-based nanoparticles for drug delivery

This invention relates to polymeric nanoparticles useful for drug delivery with target molecules bonded to the surface of the particles and having sizes of up to 1000 nm, preferably 1 nm to 400 nm, more preferably 1 nm to 200 nm, that are dispersed homogeneously in aqueous solution. The target drug/target substance is covalently bonded to the novel polymeric nanoparticles to secure them from outer intervention in vivo or cell culture in vitro until they are exposed at the target site within the cell. This invention also relates to microemulsion polymerization techniques useful for preparing the novel nanoparticles.

Nanoparticles for drug-delivery

[object Object]

The present invention provides N-alkylthio &#x3b2;-lactams and disulfide compounds (e.g., alkyl-coenzyme A asymmetric disulfides or aryl-alkyl disulfides), compositions containing such compounds, and method of their use as anti-bacterial agents.

Asymmetric disulfides and aryl-alkyl disulfides as anti-bacterial agents

This invention describes the discovery and synthesis of N-thiolated 2-oxazolidinones as a new class of anti bacterial agents. These compounds can be synthesized from 2-oxazolidinones by Ndeprotection and N-sulfenylation. These new substances were found to exhibit potent anti-bacterial activity, including bacteriostatic properties againstspp., including methicillin resistant(MRSA), andspp., including

Derivative N-thiolated 2-oxazolidinone antibiotics

Growing community of inventors

Wesley Chapel, FL, United States of America

Edward Turos